Have a feature idea you'd love to see implemented?
Let us know!
GH Guardant Health Inc
Price (delayed)
$30.98
Market cap
$3.83B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.28
Enterprise value
$4.45B
Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The Guardant Health
Highlights
The gross profit has grown by 29% YoY and by 8% from the previous quarter
Guardant Health's revenue has increased by 29% YoY and by 8% from the previous quarter
GH's equity has shrunk by 126% YoY
Guardant Health's net income has decreased by 19% YoY and by 4.4% QoQ
Key stats
What are the main financial stats of GH
Market
Valuations
Earnings
Shares outstanding
123.55M
Market cap
$3.83B
Enterprise value
$4.45B
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
5.51
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.43
Revenue
$692.26M
EBIT
-$509.8M
EBITDA
-$467M
Free cash flow
-$274.36M
Per share
Balance sheet
Liquidity
EPS
-$4.28
Free cash flow per share
-$2.23
Book value per share
-$0.49
Revenue per share
$5.63
TBVPS
$12.42
Total assets
$1.54B
Total liabilities
$1.6B
Debt
$1.31B
Equity
-$60.1M
Working capital
$1.03B
Debt to equity
-21.83
Current ratio
6.22
Quick ratio
5.51
Net debt/EBITDA
-1.34
Margins
Efficiency
Dividend
EBITDA margin
-67.5%
Gross margin
60.3%
Net margin
-74%
Operating margin
-74.4%
Return on assets
-30.9%
Return on equity
-1,240.3%
Return on invested capital
-28.9%
Return on capital employed
-38%
Return on sales
-73.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
GH stock price
How has the Guardant Health stock price performed over time
Intraday
0.98%
1 week
2.55%
1 month
48.66%
1 year
35.17%
YTD
14.53%
QTD
35.05%
Financial performance
How have Guardant Health's revenue and profit performed over time
Revenue
$692.26M
Gross profit
$417.53M
Operating income
-$515.14M
Net income
-$512.41M
Gross margin
60.3%
Net margin
-74%
The gross profit has grown by 29% YoY and by 8% from the previous quarter
Guardant Health's revenue has increased by 29% YoY and by 8% from the previous quarter
The company's operating margin rose by 22% YoY and by 6% QoQ
Guardant Health's net income has decreased by 19% YoY and by 4.4% QoQ
Growth
What is Guardant Health's growth rate over time
Valuation
What is Guardant Health stock price valuation
P/E
N/A
P/B
N/A
P/S
5.51
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.43
The EPS has declined by 5% year-on-year and by 3.6% since the previous quarter
GH's equity has shrunk by 126% YoY
The P/S is 73% below the 5-year quarterly average of 20.7 but 15% above the last 4 quarters average of 4.8
Guardant Health's revenue has increased by 29% YoY and by 8% from the previous quarter
Efficiency
How efficient is Guardant Health business performance
The ROE has plunged by 187% from the previous quarter
Guardant Health's ROIC has plunged by 71% YoY and by 12% from the previous quarter
GH's ROA is down by 21% year-on-year and by 8% since the previous quarter
The return on sales is up by 8% year-on-year and by 2.9% since the previous quarter
Dividends
What is GH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for GH.
Financial health
How did Guardant Health financials performed over time
Guardant Health's total assets is 3.8% less than its total liabilities
Guardant Health's total assets has decreased by 14% YoY and by 4.4% from the previous quarter
GH's current ratio is up by 4.7% year-on-year but it is down by 2.8% since the previous quarter
GH's equity has shrunk by 126% YoY
GH's debt to equity has surged by 97% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.